OBJECTIVES: To investigate the relationship of dual-phase dual-energy CT (DE-CT) and @entity5 size in the evaluation of the response to anti- @entity470 therapy in @entity1 with advanced @entity1149 ( @entity1149 ). METHODS: Dual-phase DE-CT was performed in 31 @entity1 with @entity1149 before the onset of anti- @entity470 ( @entity3866 ) therapy and as follow-up (mean 8 weeks). @entity1496 uptake (IU; mg/mL) was quantified using prototype software in arterial and venous phases; arterial enhancement fraction (AEF) was calculated. The change of IU before and after therapy onset was compared with anatomical evaluation in maximal transverse diameter and volume (responders vs. non-responders). RESULTS: A significant decrease of IU in venous phase was proved in responders according to all anatomical parameters (p=0.002-0.016). In groups of non-responders, a significant change of IU was not proved with variable trends of development. The most significant change was observed using the anatomical parameter of volume (cut-off 73 %). A significant difference of percentage change in AEF was proved between responding and non-responders (p=0.019-0.043). CONCLUSION: Dual-phase DE-CT with @entity1496 uptake quantification is a feasible method with potential benefit in advanced assessment of anti- @entity470 therapy response. We demonstrated a decrease in vascularization in the responding primary @entity5 and non-significant variable development of vascularization in @entity5 . KEY POINTS:     Dual-phase DE-CT is feasible for vascularization assessment of @entity1149 with anti- @entity470 therapy.     There was a significant decrease of @entity1496 uptake in responding @entity5 .     There was a non-significant and variable development in @entity5 .     There was significant difference of AEF percentage change between responders and non-responders.

Dual-Phase Dual-Energy CT in XXXX Treated with @entity3866 for Advanced @entity1149 : Possible Benefits of @entity1496 Quantification in Response Assessment.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1496 :: ('MESH:D007455', 'Chemical') :: ['iodine', 'Iodine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'non-responding tumours', 'tumour'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib']
@entity1 :: (9606,Species) :: ['Patients']
